IMDX vs PFE · rev $271.0K vs P/E 20, rev $15.03B
Insight Molecular Diagnostics Inc. (IMDX) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on US.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported IMDX revenue for 2026-06-30 was $271.0K. Net income was -$15.6M. IMDX currently screens at market cap $0.
Latest reported PFE revenue for 2026-06-28 was $15.03B. Net income was -$248.0M. Revenue was up 4.0% from 2026-03-29 to 2026-06-28. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
IMDX currently screens at market cap $0. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the IMDX and PFE stock pages for the full models.
Not investment advice.